Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;62(1):70-75.
doi: 10.1002/mus.26894. Epub 2020 Apr 28.

Paravertebral block for radiologically inserted gastrostomy tube placement in amyotrophic lateral sclerosis

Affiliations

Paravertebral block for radiologically inserted gastrostomy tube placement in amyotrophic lateral sclerosis

Steven B Porter et al. Muscle Nerve. 2020 Jul.

Abstract

Introduction: Radiologically inserted gastrostomy (RIG) placement in patients with amyotrophic lateral sclerosis (ALS) carries risks related to periprocedural sedation and analgesia. To minimize these risks, we used a paravertebral block (PVB) technique for RIG placement.

Methods: We retrospectively reviewed patients with ALS undergoing RIG placement under PVB between 2013 and 2017.

Results: Ninety-nine patients with ALS underwent RIG placement under PVB. Median (range) age was 66 (28 to 86) years, ALS Functional Rating Scale-Revised score was 27 (6 to 45), and forced vital capacity was 47% (8%-79%) at time of RIG placement. Eighty-five (85.9%) patients underwent RIG placement as outpatients, with a mean postanesthesia care unit stay of 2.3 hours. The readmission rate was 4% at both 1 and 30 days postprocedure.

Discussion: PVB for RIG placement has a low rate of adverse events and provides effective periprocedural analgesia in patients with ALS, the majority of whom can be treated as outpatients.

Keywords: amyotrophic lateral sclerosis; analgesia; anesthesia; gastrostomy tube; paravertebral block; radiologically inserted gastrostomy.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43:1316-1322.
    1. Kasarskis EJ, Mendiondo MS, Matthews DE, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014;99:792-803.
    1. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218-1226.
    1. EFNS Task Force on Diagnosis Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19:360-375.
    1. National Clinical Guideline Centre (UK). Motor Neurone Disease: Assessment and Management. London: National Institute for Health and Care Excellence; 2016.

LinkOut - more resources